Datapoint: Opdivo Becomes First Immunotherapy Approved to Treat Gastric Cancer

The FDA on April 16 approved Bristol Myers Squibb’s blockbuster cancer drug Opdivo as a first-line treatment for gastric cancer, gastroesophageal junction cancer and advanced or spreading esophageal adenocarcinoma. The PD-1 inhibitor is the first immunotherapy approved to treat gastric cancer. Opdivo was first approved to treat advanced melanoma in December 2014. In that indication, the drug holds covered or better status for 52% of all insured lives.

SOURCE: MMIT Analytics, as of 4/21/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 25

Datapoint: Kaiser Dominates 2022 Star Ratings

https://www.mmitnetwork.com/wp-content/uploads/2021/08/post-default-img.jpg
October 18

Datapoint: AmeriHealth Caritas to Enter Exchange Market

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 14

Datapoint: Ochsner to Launch MA Org in Louisiana

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today